Key facts
- Serenatis Bio’s last known valuation is $4.6M (Apr 2025).
- It has raised $1.3M; the latest was Early Stage VC ($1.3M) in Apr 2025.
- Notable investors include Zinc, Novaterra Holding, P53.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Serenatis Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Serenatis Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Serenatis Bio
Operator of a small-molecule drug discovery biotech intended to transform the treatment landscape for obsessive-compulsive disorder (OCD). The company offers three novel drug candidates with unique mechanisms targeting glutamate and dopamine pathways, enabling Healthcare professionals to access precision-medicine-based therapies tailored to individual neurobiological profiles, with the aim of improving efficacy, speeding onset, and reducing side effects.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2024
- Employees
- 2
- Website
- serenatisbio.com/
- Ownership
- Privately Held (backing)
Serenatis Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Serenatis Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Serenatis Bio in its N-PORT filings yet. We sweep new filings monthly.